刘勇,谭宁,陈玉怡,李欣,周颖玲,陈纪言,罗建方,何鹏程,谢年谨

• 1:广东省心血管病研究所广东省人民医院广东省医学科学院
• 2:广东省东莞市人民医院
• 3:中山大学公共卫生学院医学统计与流行病学教研室

摘要(Abstract)：

目的观察不同剂量的阿托伐他汀治疗对慢性肾病患者行冠状动脉介入术(PCI)后对比剂肾病的影响。方法将192例拟行PCI术慢性肾病(CKD,eGFR<60ml·min-1·1.73m-2)患者,采用随机数表法分为强化阿托伐他汀治疗组(96例,其中11例患者因未行PCI术退出研究)和常规剂量阿托伐他汀治疗组(96例),在全部采用水化治疗基础上,强化治疗组患者在住院期间给予阿托伐他40mg/d,对照组给予常规剂量阿托伐他汀20mg/d,观察PCI术前基础血清肌酐(Scr)等指标,术后48～72hScr。使用简化MDRD方程估计肾小球滤过率(eGFR),eGFR<30m·lmin-1·1.73m-2定义为重度CKD。PCI术后48～72h血清肌酐(Scr)的绝对值升高44.2μmol/L定义为对比剂肾病。观察两组对比剂肾病及其他临床不良事件。结果最终入选的181例患者中有26例(14%)患者发生了对比剂肾病,强化治疗组对比剂肾病发生率低于常规治疗组(12%比17%,χ2=0.348,P=0.348),但两组间差异无统计学意义。两组患者需要肾脏替代治疗(RRT,0比5%,P=0.061)、死亡率(6%比6%,χ2=0.011,P=0.918)、需要主动脉球囊反博(IABP)治疗(15%比12%,χ2=0.577,P=0.448)、急性心力衰竭(6%比3%,P=0.447)等临床不良事件发生率间差异均无统计学意义。对糖尿病(14%比25%,χ2=1.071,P=0.301)、重度CKD(10%比60%,P=0.057)等进行亚组分析,统计结果显示强化治疗组造影剂肾病发生率均低于常规治疗组,但两组间差异均无统计学意义。结论强化阿托伐他汀对慢性肾病患者对比剂肾病的发生可能无预防作用。

关键词(KeyWords)： 阿托伐他汀;血管成形术,经腔,经皮冠状动脉;肾病

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 刘勇,谭宁,陈玉怡,李欣,周颖玲,陈纪言,罗建方,何鹏程,谢年谨

参考文献(References)：

• [1]McCullough PA,Adam A,Becker CR,et al.Epidemiology and prognostic implications of contrast-induced nephropathy.Am J Cardiol,2006,98:5K-13K.
• [2]Mehran R,Aymong ED,Nikolsky E,et al.A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention.J Am Coll Cardiol,2004,44:1393-1399.
• [3]Gleeson TG,Bulugahapitiya S.Contrast-induced nephropathy.Am J Roentgenol,2004,183:1673-1689.
• [4]Trivedi HS,Moore H,Nasr S,et al.A randomized prospective trial to assess the role of saline hydration on the development of contrast nephrotoxicity.Nephron Clin Pract,2003,93:C29-C34.
• [5]Attallah N,Yassine L,Musial J,et al.The potential role of statins in contrast nephropathy.Clin Nephrol,2004,62:273-278.
• [6]Khanal S,Attallah N,Smith DE,et al.Statin therapy reduces contrast-induced nephropathy:an analysis of contemporary percutaneous interventions.Am J Med,2005,118:843-849.
• [7]Patti P,Nusca A,Chello M,et al.Usefulness of statin pretreatment to prevent contrast-induced nephropathy and to improve long-term outcome in patients undergoing percutaneous coronary intervention.Am J Cardiol,2008,101:279-285.
• [8]Levey AS,Greene T,Kusek J,et al.A simplified equation to predict GFR from serum creatinine.J Am Soc Nephrol,2000,11:155A.
• [9]Rauch D,Drescher P,Pereira FJ,et al.Comparison of iodinated contrast media-induced renal vasoconstriction in human,rabbit,dog,and pig arteries.Invest Radiol,1997,32:315-319.
• [10]Louie EK,Al-Sadir J,Emmanouel D.Quantitative effects of osmotic diuresis following angiographic contrast administration.Cathet Cardiovasc Diagn,1986,12:235-239.
• [11]Chan AW,Bhatt DL,Chew DP,et al.Early and sustained survival benefit associated with statin therapy at the time of percutaneous coronary intervention.Circulation,2002,105:691-696.
• [12]Shepherd J,Kastelein JJ,Bittner V,et al.Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease:the TNT(Treating to New Targets)study.J Am Coll Cardiol,2008,51:1448-1454.
• [13]Harper CR,Jacobson TA.Managing dyslipidemia in chronic kidney disease.J Am Coll Cardiol,2008,51:2375-2384.
• [14]John S,Schneider MP,Delles C,et al.Lipid-independent effects of statins on endothelial function and bioavailability of nitric oxide in hypercholesterolemic patients.Am Heart J,2005,149Suppl:473.e1-e10.
• [15]Bonnet J,McPherson R,Tedgui A,et al.Comparative effects of 10-mg versus80-mg Atorvastatin on high-sensitivity C-reactive protein in patients with stable coronary artery disease:results of the CAP(Comparative Atorvastatin Pleiotropic effects)study.Clin Ther,2008,30:2298-2313.
• [16]Jo SH,Koo BK,Park JS,et al.Prevention of radiocontrast-medium-induced nephropathy using short-term high-dose simvastatin in patients with renal insufficiency undergoing coronary angiography(PROMISS)trial-a randomized controlled study.Am Heart J,2008,155Suppl:499.e1-e8.
• [17]Toso A,Maioli M,Leoncini M,et al.Usefulness of atorvastatin(80mg)in prevention of contrast-induced nephropathy in patients with chronic renal disease.Am J Cardiol,2010,105:288-292.